These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

496 related articles for article (PubMed ID: 8839204)

  • 21. Neonatal mouse assay for tumorigenicity: alternative to the chronic rodent bioassay.
    Flammang TJ; Tungeln LS; Kadlubar FF; Fu PP
    Regul Toxicol Pharmacol; 1997 Oct; 26(2):230-40. PubMed ID: 9356286
    [TBL] [Abstract][Full Text] [Related]  

  • 22. NTP technical report on the toxicology and carcinogenesis studies of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (CAS No. 1746-01-6) in female Harlan Sprague-Dawley rats (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 2006 Apr; (521):4-232. PubMed ID: 16835633
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Animal carcinogenicity studies: implications for the REACH system.
    Knight A; Bailey J; Balcombe J
    Altern Lab Anim; 2006 Mar; 34 Suppl 1():139-47. PubMed ID: 16555967
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alternative models for carcinogenicity testing: weight of evidence evaluations across models.
    Cohen SM
    Toxicol Pathol; 2001; 29 Suppl():183-90. PubMed ID: 11695556
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An enhanced 13-week bioassay: an alternative to the 2-year bioassay to screen for human carcinogenesis.
    Cohen SM
    Exp Toxicol Pathol; 2010 Sep; 62(5):497-502. PubMed ID: 19616417
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of the ability of a battery of three in vitro genotoxicity tests to discriminate rodent carcinogens and non-carcinogens I. Sensitivity, specificity and relative predictivity.
    Kirkland D; Aardema M; Henderson L; Müller L
    Mutat Res; 2005 Jul; 584(1-2):1-256. PubMed ID: 15979392
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An enhanced thirteen-week bioassay as an alternative for screening for carcinogenesis factors.
    Cohen SM
    Asian Pac J Cancer Prev; 2010; 11(1):15-7. PubMed ID: 20593920
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluating consistency in the interpretation of NTP rodent cancer bioassays: an examination of mouse lung tumor effects in the 4-MEI study.
    Haseman JK
    Regul Toxicol Pharmacol; 2013 Jun; 66(1):109-15. PubMed ID: 23545072
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A critical appraisal of the value of the mouse cancer bioassay in safety assessment.
    Alden CL; Smith PF; Piper CE; Brej L
    Toxicol Pathol; 1996; 24(6):722-5. PubMed ID: 8994300
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Medium-term bioassays in rats for rapid detection of the carcinogenic potential of chemicals.
    Shirai T; Hirose M; Ito N
    IARC Sci Publ; 1999; (146):251-72. PubMed ID: 10353390
    [No Abstract]   [Full Text] [Related]  

  • 31. Speculations on the rodent carcinogenicity of 30 chemicals currently under evaluation in rat and mouse bioassays organised by the U.S. National Toxicology Program.
    Bootman J
    Environ Mol Mutagen; 1996; 27(3):237-43. PubMed ID: 8625960
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oxymetholone: II. Evaluation in the Tg-AC transgenic mouse model for detection of carcinogens.
    Holden HE; Stoll RE; Blanchard KT
    Toxicol Pathol; 1999; 27(5):507-12. PubMed ID: 10528629
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evolution of the uses of rats and mice for assessing carcinogenic risk from chemicals in humans.
    Ward JM
    Asian Pac J Cancer Prev; 2010; 11(1):18. PubMed ID: 20593921
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of discounting certain tumor types/sites on evaluations of carcinogenicity in laboratory animals.
    Karstadt M; Haseman JK
    Am J Ind Med; 1997 May; 31(5):485-94. PubMed ID: 9099349
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Implications of the lack of accuracy of the lifetime rodent bioassay for predicting human carcinogenicity.
    Ennever FK; Lave LB
    Regul Toxicol Pharmacol; 2003 Aug; 38(1):52-7. PubMed ID: 12878054
    [TBL] [Abstract][Full Text] [Related]  

  • 36. International regulatory needs for development of an IATA for non-genotoxic carcinogenic chemical substances.
    Jacobs MN; Colacci A; Louekari K; Luijten M; Hakkert BC; Paparella M; Vasseur P
    ALTEX; 2016; 33(4):359-392. PubMed ID: 27120445
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Epidemiological and experimental applications to occupational cancer prevention.
    Vainio H; Hemminki K
    J UOEH; 1989 Mar; 11 Suppl():323-45. PubMed ID: 2664947
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of the ability of a battery of three in vitro genotoxicity tests to discriminate rodent carcinogens and non-carcinogens II. Further analysis of mammalian cell results, relative predictivity and tumour profiles.
    Kirkland D; Aardema M; Müller L; Makoto H
    Mutat Res; 2006 Sep; 608(1):29-42. PubMed ID: 16769241
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The relation between carcinogenesis and mutagenesis: a re-evaluation].
    Bartsch H; Malaveille C
    Bull Acad Natl Med; 1989 Nov; 173(8):1005-12; discussion 1013-5. PubMed ID: 2633853
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Historical perspective on the use of animal bioassays to predict carcinogenicity: evolution in design and recognition of utility.
    Beyer LA; Beck BD; Lewandowski TA
    Crit Rev Toxicol; 2011 Apr; 41(4):321-38. PubMed ID: 21438739
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.